These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 1695181)

  • 1. Tissue plasminogen activator (PA) and urokinase inhibitor in the tissue of neutral and hyperthyroid goitre.
    Piotrowski Z; Soszka T
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(1):37-43. PubMed ID: 1695181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in pericardial morphology and fibrinolytic activity during cardiopulmonary bypass.
    Nkere UU; Whawell SA; Thompson EM; Thompson JN; Taylor KM
    J Thorac Cardiovasc Surg; 1993 Aug; 106(2):339-45. PubMed ID: 8341074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM; Greco WR
    Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.
    Kruithof EK; Tran-Thang C; Bachmann F
    Thromb Haemost; 1986 Feb; 55(1):65-9. PubMed ID: 3085266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
    Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
    Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of heat shock on the expression of urokinase-type plasminogen activator receptor in human umbilical vein endothelial cells.
    Fukao H; Hagiya Y; Ueshima S; Okada K; Takaishi T; Izaki S; Matsuo O
    Thromb Haemost; 1996 Feb; 75(2):352-8. PubMed ID: 8815589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA) in orthotopic liver transplantation (OLT).
    Himmelreich G; Dooijewaard G; Breinl P; Bechstein WO; Neuhaus P; Kluft C; Riess H
    Thromb Haemost; 1993 Jan; 69(1):56-9. PubMed ID: 8446939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased plasminogen activator inhibition levels in malignancy.
    de Jong E; Knot EA; Piket D; Iburg AH; Rijken DC; Veenhof KH; Dooijewaard G; ten Cate JW
    Thromb Haemost; 1987 Apr; 57(2):140-3. PubMed ID: 3110994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators.
    Korner G; Bjornsson TD; Vlodavsky I
    J Cell Physiol; 1993 Mar; 154(3):456-65. PubMed ID: 8436596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.
    Tabengwa EM; Grenett HE; Benza RL; Abou-Agag LH; Tresnak JK; Wheeler CG; Booyse FM
    Alcohol Clin Exp Res; 2001 Feb; 25(2):163-70. PubMed ID: 11236828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased peritoneal tissue plasminogen activator during prolonged laparoscopic surgery.
    Brokelman WJ; Holmdahl L; Janssen IM; Falk P; Bergström M; Klinkenbijl JH; Reijnen MM
    J Surg Res; 2009 Jan; 151(1):89-93. PubMed ID: 18541262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.
    Wilson MJ; Ludowese C; Sinha AA; Estensen RD
    Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activators in the intestine of patients with inflammatory bowel disease.
    de Bruin PA; Crama-Bohbouth G; Verspaget HW; Verheijen JH; Dooijewaard G; Weterman IT; Lamers CB
    Thromb Haemost; 1988 Oct; 60(2):262-6. PubMed ID: 3146142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.